By any measure, marijuana has steadily become more socially kosher, according to both opinion polls and state and local policies. And even as U.S. Attorney General Jeff Sessions has voiced his intention to once again harshly punish pot users, other Trump appointees have pushed back against the increasingly unpopular idea.
A new study of young epileptic sufferers released this month, though, reminds us that it won’t be weekend smokers looking to wind down who stand to gain the most from marijuana’s growing acceptance.
As part of a double-blind clinical trial, scientists followed 225 children and adults dealing with a severe, often untreatable form of epilepsy called Lennox-Gastaut syndrome. The volunteers, on average 16-years-old, were either given a placebo or varying doses of cannabidiol, one of the two major components of marijuana. Those who took cannabidiol (in liquid drops), regardless of the dose, were significantly more likely to report fewer seizures